Pictet Asset Management SA Boosts Holdings in Edwards Lifesciences Co. (NYSE:EW)

Pictet Asset Management SA grew its holdings in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 9.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 970,579 shares of the medical research company’s stock after purchasing an additional 82,274 shares during the quarter. Pictet Asset Management SA owned 0.16% of Edwards Lifesciences worth $125,739,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $29,000. Northwest Investment Counselors LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $30,000. Liberty Wealth Management LLC raised its holdings in Edwards Lifesciences by 362.3% during the third quarter. Liberty Wealth Management LLC now owns 245 shares of the medical research company’s stock worth $29,000 after purchasing an additional 192 shares in the last quarter. Arlington Partners LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $34,000. Finally, Mascoma Wealth Management LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $38,000. 82.54% of the stock is owned by institutional investors and hedge funds.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,550 shares of the stock in a transaction that occurred on Tuesday, February 15th. The shares were sold at an average price of $110.09, for a total value of $3,583,429.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Martha H. Marsh sold 28,722 shares of the stock in a transaction that occurred on Thursday, April 28th. The shares were sold at an average price of $108.09, for a total transaction of $3,104,560.98. Following the completion of the sale, the director now directly owns 26,777 shares of the company’s stock, valued at approximately $2,894,325.93. The disclosure for this sale can be found here. Insiders have sold a total of 282,581 shares of company stock valued at $30,556,623 in the last quarter. Company insiders own 1.29% of the company’s stock.

NYSE EW opened at $97.55 on Friday. Edwards Lifesciences Co. has a 12 month low of $88.01 and a 12 month high of $131.73. The company has a 50-day moving average of $112.06 and a 200-day moving average of $114.55. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.41 and a quick ratio of 2.64. The company has a market cap of $60.65 billion, a P/E ratio of 39.98, a P/E/G ratio of 2.82 and a beta of 1.16.

Edwards Lifesciences (NYSE:EWGet Rating) last issued its earnings results on Tuesday, April 26th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. Edwards Lifesciences had a return on equity of 25.80% and a net margin of 28.72%. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter in the previous year, the business earned $0.54 EPS. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

EW has been the topic of a number of research analyst reports. Morgan Stanley cut their price objective on shares of Edwards Lifesciences from $148.00 to $136.00 and set an “overweight” rating on the stock in a report on Thursday, January 27th. UBS Group raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the company from $121.00 to $126.00 in a report on Wednesday, February 2nd. Raymond James cut their target price on shares of Edwards Lifesciences from $134.00 to $126.00 and set an “outperform” rating on the stock in a report on Thursday, January 27th. Piper Sandler cut their target price on shares of Edwards Lifesciences from $133.00 to $125.00 in a report on Thursday, January 27th. Finally, Stifel Nicolaus cut their target price on shares of Edwards Lifesciences from $132.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, January 27th. Five equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Buy” and an average target price of $128.29.

Edwards Lifesciences Company Profile (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Recommended Stories

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.